- Home
- TOVX vs BIVI Comparison
TOVX vs BIVI Comparison
Compare TOVX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOVX | BIVI |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 13.3M |
| IPO Year | 2012 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TOVX | BIVI |
|---|---|---|
| Price | $0.23 | $1.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 229.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $1.06 |
| 52 Week High | $0.86 | $8.34 |
Technical Indicators
Market Signals| Indicator | TOVX | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 38.88 |
| Support Level | $0.22 | $1.22 |
| Resistance Level | $0.27 | $1.51 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 17.97 | 12.12 |
Price Performance
Historical ComparisonAbout TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.